Engineered immune cells take on recurrent brain tumors in first human trial
NCT ID NCT06964737
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This early-phase study tests a new treatment for people whose high-grade glioma (a type of brain cancer) has returned after previous therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called GARP found on tumor cells. The main goals are to find the safest dose and to see if this approach can help control the disease. About 30 adults with recurrent grade III or IV glioma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WHO GRADE 4 GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.